UNC93B1 (Unc-93 Homolog B1)

The strong correlation between UNC93B1 overexpression and adverse clinical outcomes underscores its potential as a dual diagnostic biomarker and therapeutic target. This work not only provides a mechanistic foundation for novel precision immunotherapies in PDAC but also establishes a robust methodological paradigm for multi-omics-driven discovery in oncology.

Knockdown of UNC93B1 expression in BRCA cell lines (MDA-MB-231, SK-BR-3) suppresses their proliferation, invasion, and other phenotypes. These results suggest that UNC93B1 may be an immunologically relevant diagnostic and prognostic biomarker for BRCA.

Overall, our study not only facilitates understanding the role of DDIT3 in breast cancer but also offers innovative insights for developing prognostic models and therapeutic strategies. Identifying the DDIT3-related prognostic signature and its association with the immune microenvironment provided a promising avenue for personalized breast cancer treatment.

We evaluated a male infant with neonatal skin/eye/mouth (SEM) HSV-1 disease, who had complete recovery after acyclovir but developed HSV-1 encephalitis at 1 year of age...This study reports an infant with recurrent HSV1 disease complicated by encephalitis associated with deleterious variants in IRF7 and UNC93B1 genes. Our results suggest that TLR3 pathway mutations may predispose neonates to recurrent severe HSV.

Additionally, model-based RSs in the immunotherapy cohort were significantly different between complete remission (CR) and other response groups. The prognosis of people with LAML can be predicted using the 8-gene signature.